These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26655275)

  • 1. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
    Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
    Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance.
    Tran AP; Ali Al-Radhawi M; Kareva I; Wu J; Waxman DJ; Sontag ED
    Front Immunol; 2020; 11():1376. PubMed ID: 32695118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
    Banissi C; Ghiringhelli F; Chen L; Carpentier AF
    Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of glioma-specific immunity in mice by "NOBEL", an insulin-like growth factor 1 receptor antisense oligodeoxynucleotide.
    Morin-Brureau M; Hooper KM; Prosniak M; Sauma S; Harshyne LA; Andrews DW; Hooper DC
    Cancer Immunol Immunother; 2015 Apr; 64(4):447-57. PubMed ID: 25579379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
    Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
    Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
    Lowenstein PR; Castro MG
    Clin Immunol; 2018 Apr; 189():43-51. PubMed ID: 28720549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Environment-responsive dendrobium polysaccharide hydrogel embedding manganese microsphere as a post-operative adjuvant to boost cascaded immune cycle against melanoma.
    Gao N; Huang Y; Jing S; Zhang M; Liu E; Qiu L; Huang J; Muhitdinov B; Huang Y
    Theranostics; 2024; 14(10):3810-3826. PubMed ID: 38994034
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice.
    Triozzi PL; Aldrich W; Achberger S; Ponnazhagan S; Alcazar O; Saunthararajah Y
    Cancer Immunol Immunother; 2012 Sep; 61(9):1441-50. PubMed ID: 22310929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional characterization of tumor antigen-specific T-cells isolated from the tumor microenvironment of sleeping beauty induced murine glioma models.
    Alghamri MS; Núñez FJ; Kamran N; Carney S; Altshuler D; Lowenstein PR; Castro MG
    Methods Enzymol; 2020; 631():91-106. PubMed ID: 31948569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
    Najem H; Khasraw M; Heimberger AB
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.
    Ghiringhelli F; Menard C; Puig PE; Ladoire S; Roux S; Martin F; Solary E; Le Cesne A; Zitvogel L; Chauffert B
    Cancer Immunol Immunother; 2007 May; 56(5):641-8. PubMed ID: 16960692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.
    Kong LY; Wu AS; Doucette T; Wei J; Priebe W; Fuller GN; Qiao W; Sawaya R; Rao G; Heimberger AB
    Clin Cancer Res; 2010 Dec; 16(23):5722-33. PubMed ID: 20921210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model.
    Maes W; Van Gool SW
    Cancer Immunol Immunother; 2011 Feb; 60(2):153-60. PubMed ID: 21120655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metronomic cyclophosphamide and metformin inhibited tumor growth and repopulated tumor-infiltrating lymphocytes in an experimental carcinoma model.
    Zaki HM; Ali KM; Abd Allah MYY; Abouelnaga AM; Abdraboh ME; Hussein O
    BMC Res Notes; 2024 Jan; 17(1):4. PubMed ID: 38167322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-inorganic hybrid nanovaccine for cancer immunotherapy.
    Zhu G; Liu Y; Yang X; Kim YH; Zhang H; Jia R; Liao HS; Jin A; Lin J; Aronova M; Leapman R; Nie Z; Niu G; Chen X
    Nanoscale; 2016 Mar; 8(12):6684-92. PubMed ID: 26947116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of regulatory T cells enhancing the anti-tumor effect of in situ vaccination in solid tumors.
    Xie YJ; Tian S; Huang M; Lu LL; Liu ZQ; Chen JH; Fan XX
    Pharmacol Res; 2024 May; 203():107174. PubMed ID: 38580185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model.
    Enríquez Pérez J; Fritzell S; Kopecky J; Visse E; Darabi A; Siesjö P
    Sci Rep; 2019 Apr; 9(1):5632. PubMed ID: 30948731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation.
    Chavez M; Silvestrini MT; Ingham ES; Fite BZ; Mahakian LM; Tam SM; Ilovitsh A; Monjazeb AM; Murphy WJ; Hubbard NE; Davis RR; Tepper CG; Borowsky AD; Ferrara KW
    Theranostics; 2018; 8(13):3611-3628. PubMed ID: 30026870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities".
    Delahousse J; Molina L; Paci A
    Cancer Lett; 2024 Aug; 598():217119. PubMed ID: 39002693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.